Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.7050
+0.0098 (1.41%)
At close: May 29, 2026, 4:00 PM EDT
0.7153
+0.0103 (1.46%)
After-hours: May 29, 2026, 4:00 PM EDT
Pasithea Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
23.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 15.06K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curis | 7.06M |
| Marker Therapeutics | 3.55M |
| Traws Pharma | 2.73M |
| Longeveron | 1.22M |
| Werewolf Therapeutics | 1.14M |
| Vistagen Therapeutics | 789.00K |
| VYNE Therapeutics | 454.00K |
KTTA News
- 3 hours ago - Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis - TheFly
- 25 days ago - Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer - TheFly
- 25 days ago - Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer - GlobeNewsWire
- 5 weeks ago - Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004 - TheFly
- 2 months ago - Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 months ago - Pasithea Therapeutics provides updated timeline on PAS-004 programs - TheFly
- 4 months ago - Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - GlobeNewsWire